FDA proposes accelerated medical device approval plan

FDA proposes accelerated medical device approval plan

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical needs are not met by current technology.

The proposed Expedited Access Premarket Approval Application for Unmet Medical Needs for Life Threatening or Irreversibly Debilitating Diseases or Conditions ("Expedited Access PMA" or "EAP") program features earlier and more interactive engagement with staff from the FDA. This will include the involvement of senior management and a collaboratively developed plan for collecting the data to support approval.

According to the FDA, EAP is not a new pathway to market, but rather an approach where all parties work together to facilitate product development under the agency's existing regulatory authorities. EAP seeks to reduce the time associated with , not just reduce the time for the premarket review. In addition to the program, the FDA has published a separate draft guidance outlining the agency's current policy on the timeline for data to be collected after product approval and what actions are available to the agency if approval conditions, such as postmarket data collection, are not met. Advice on the use of surrogate or independent markers to support approval, similar to those seen for accelerated approval of prescription drugs, is included in the guidance.

"We are excited to offer a proposed program for expedited access for certain high-risk ," Jeffrey Shuren, M.D., director of the FDA's Center for Devices and Radiological Health, said in a statement. "The program allows manufacturers to engage early and often with the agency. We expect most devices that enter this program will be in the pre-clinical trial phase."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

FDA approves expanded indication for CRT devices

Apr 15, 2014

(HealthDay)—The U.S. Food and Drug Administration has approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers (CRT-P) and eight cardiac resynchronization ...

Recommended for you

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

Aug 21, 2014

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

User comments